84 related articles for article (PubMed ID: 11429580)
1. Are all cancer genes equal?
Bartek J; Lukas J
Nature; 2001 Jun; 411(6841):1001-2. PubMed ID: 11429580
[No Abstract] [Full Text] [Related]
2. Specific protection against breast cancers by cyclin D1 ablation.
Yu Q; Geng Y; Sicinski P
Nature; 2001 Jun; 411(6841):1017-21. PubMed ID: 11429595
[TBL] [Abstract][Full Text] [Related]
3. The reciprocal dance between cancer and development.
Chodosh LA
N Engl J Med; 2002 Jul; 347(2):134-6. PubMed ID: 12110743
[No Abstract] [Full Text] [Related]
4. Suppression of Neu-induced mammary tumor growth in cyclin D1 deficient mice is compensated for by cyclin E.
Bowe DB; Kenney NJ; Adereth Y; Maroulakou IG
Oncogene; 2002 Jan; 21(2):291-8. PubMed ID: 11803472
[TBL] [Abstract][Full Text] [Related]
5. The role of Ink4a/Arf in ErbB2 mammary gland tumorigenesis.
D'Amico M; Wu K; Di Vizio D; Reutens AT; Stahl M; Fu M; Albanese C; Russell RG; Muller WJ; White M; Negassa A; Lee HW; DePinho RA; Pestell RG
Cancer Res; 2003 Jun; 63(12):3395-402. PubMed ID: 12810676
[TBL] [Abstract][Full Text] [Related]
6. Requirement for CDK4 kinase function in breast cancer.
Yu Q; Sicinska E; Geng Y; Ahnström M; Zagozdzon A; Kong Y; Gardner H; Kiyokawa H; Harris LN; Stål O; Sicinski P
Cancer Cell; 2006 Jan; 9(1):23-32. PubMed ID: 16413469
[TBL] [Abstract][Full Text] [Related]
7. Cyclin d1 overexpression sensitizes breast cancer cells to fenretinide.
Pirkmaier A; Yuen K; Hendley J; O'Connell MJ; Germain D
Clin Cancer Res; 2003 May; 9(5):1877-84. PubMed ID: 12738746
[TBL] [Abstract][Full Text] [Related]
8. Identification of cyclin D1- and estrogen-regulated genes contributing to breast carcinogenesis and progression.
Yang C; Trent S; Ionescu-Tiba V; Lan L; Shioda T; Sgroi D; Schmidt EV
Cancer Res; 2006 Dec; 66(24):11649-58. PubMed ID: 17178859
[TBL] [Abstract][Full Text] [Related]
9. ErbB-2 induces the cyclin D1 gene in prostate epithelial cells in vitro and in vivo.
Casimiro M; Rodriguez O; Pootrakul L; Aventian M; Lushina N; Cromelin C; Ferzli G; Johnson K; Fricke S; Diba F; Kallakury B; Ohanyerenwa C; Chen M; Ostrowski M; Hung MC; Rabbani SA; Datar R; Cote R; Pestell R; Albanese C
Cancer Res; 2007 May; 67(9):4364-72. PubMed ID: 17483350
[TBL] [Abstract][Full Text] [Related]
10. Cyclin D1 overexpression and response to bortezomib treatment in a breast cancer model.
Ishii Y; Pirkmaier A; Alvarez JV; Frank DA; Keselman I; Logothetis D; Mandeli J; O'Connell MJ; Waxman S; Germain D
J Natl Cancer Inst; 2006 Sep; 98(17):1238-47. PubMed ID: 16954476
[TBL] [Abstract][Full Text] [Related]
11. Estrogen receptor activation at serine 305 is sufficient to upregulate cyclin D1 in breast cancer cells.
Balasenthil S; Barnes CJ; Rayala SK; Kumar R
FEBS Lett; 2004 Jun; 567(2-3):243-7. PubMed ID: 15178330
[TBL] [Abstract][Full Text] [Related]
12. Cyclopentenone causes cell cycle arrest and represses cyclin D1 promoter activity in MCF-7 breast cancer cells.
Hsiang CH; Straus DS
Oncogene; 2002 Mar; 21(14):2212-26. PubMed ID: 11948404
[TBL] [Abstract][Full Text] [Related]
13. Transgenic mice with mammary gland targeted expression of human cortactin do not develop (pre-malignant) breast tumors: studies in MMTV-cortactin and MMTV-cortactin/-cyclin D1 bitransgenic mice.
van Rossum AG; van Bragt MP; Schuuring-Scholtes E; van der Ploeg JC; van Krieken JH; Kluin PM; Schuuring E
BMC Cancer; 2006 Mar; 6():58. PubMed ID: 16536875
[TBL] [Abstract][Full Text] [Related]
14. Paget's disease of the nipple: a copy number of the genes ERBB2 and CCND1 versus expression of the proteins ERBB-2 and cyclin D1.
Mrhalova M; Kodet R
Neoplasma; 2003; 50(6):396-402. PubMed ID: 14689059
[TBL] [Abstract][Full Text] [Related]
15. Cyclin D1 and pancreatic carcinoma: a proliferative agonist and chemotherapeutic antagonist.
Diehl JA; Benzeno S
Clin Cancer Res; 2005 Aug; 11(16):5665-7. PubMed ID: 16115900
[No Abstract] [Full Text] [Related]
16. Is Cyclin D1-CDK4 kinase a bona fide cancer target?
Malumbres M; Barbacid M
Cancer Cell; 2006 Jan; 9(1):2-4. PubMed ID: 16413464
[TBL] [Abstract][Full Text] [Related]
17. Cyclin D1 is necessary but not sufficient for anchorage-independent growth of rat mammary tumor cells and is associated with resistance of the Copenhagen rat to mammary carcinogenesis.
Li YJ; Song R; Korkola JE; Archer MC; Ben-David Y
Oncogene; 2003 May; 22(22):3452-62. PubMed ID: 12776197
[TBL] [Abstract][Full Text] [Related]
18. Tumors initiated by constitutive Cdk2 activation exhibit transforming growth factor beta resistance and acquire paracrine mitogenic stimulation during progression.
Corsino P; Davis B; Law M; Chytil A; Forrester E; Nørgaard P; Teoh N; Law B
Cancer Res; 2007 Apr; 67(7):3135-44. PubMed ID: 17409420
[TBL] [Abstract][Full Text] [Related]
19. Enhanced skin carcinogenesis in cyclin D1-conditional transgenic mice: cyclin D1 alters keratinocyte response to calcium-induced terminal differentiation.
Yamamoto H; Ochiya T; Takeshita F; Toriyama-Baba H; Hirai K; Sasaki H; Sasaki H; Sakamoto H; Yoshida T; Saito I; Terada M
Cancer Res; 2002 Mar; 62(6):1641-7. PubMed ID: 11912134
[TBL] [Abstract][Full Text] [Related]
20. Cyclin D1-dependent kinase activity in murine development and mammary tumorigenesis.
Landis MW; Pawlyk BS; Li T; Sicinski P; Hinds PW
Cancer Cell; 2006 Jan; 9(1):13-22. PubMed ID: 16413468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
